Inulin Acetate Microparticles Dual Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants, such as alum, primarily stimulate humoral immune responses and are inadequate for generating strong and long-lasting cellular immune responses required for diseases like cancer, malaria, and HIV, necessitating the development of novel adjuvants that can elicit both humoral and cellular immune responses.
Innovation Solution
Formulating beta-inulin and its derivative, inulin acetate, as microparticles or nanoparticles to serve as adjuvants and antigen delivery systems, which stimulate immune responses by encapsulating or associating with active agents, thereby enhancing both Th1 and Th2 immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If alum is used as an adjuvant, then humoral immune response is stimulated, but cellular immune response is insufficient
Solution Approach 1:
The patent uses composite materials by combining inulin (a polysaccharide) with aluminum salts to create inulin acetate microparticles. This composite structure enables the adjuvant to stimulate both humoral and cellular immune responses, overcoming the limitation of alum which only stimulates humoral responses. The composite material integrates the benefits of both components to achieve dual immune response stimulation.
Solution Approach 2:
The patent modifies the chemical parameters of inulin through acetylation to create inulin acetate with specific degree of substitution (DS) values. This parameter change transforms the physical and chemical properties of the material, enabling it to function as a effective adjuvant that can stimulate both Th1 and Th2 immune responses, thereby resolving the contradiction between ease of manufacture and adaptability.
2Reliability
If traditional adjuvants are used, then vaccine potency is limited, but novel adjuvant formulations require complex manufacturing processes
Solution Approach 1:
The inulin acetate microparticle formulation serves multiple functions simultaneously: it acts as an adjuvant to stimulate immune responses, as an antigen delivery system to enhance antigen presentation, and as a stable formulation that can be stored at ambient temperatures. This multi-functionality increases vaccine potency without requiring separate complex systems for each function.
Solution Approach 2:
The inulin acetate microparticles exhibit self-service properties by providing sustained antigen release and maintaining stability without requiring cold-chain storage infrastructure. The formulation inherently provides its own stability and delivery mechanisms, reducing the need for complex external support systems and simplifying manufacturing and distribution.
3Reliability
If vaccines require cold-chain storage, then potency is maintained, but distribution and storage become complex and costly
Solution Approach 1:
The patent modifies the physical and chemical parameters of the vaccine formulation through inulin acetate microparticle creation, which fundamentally changes the stability profile of the vaccine. This parameter change enables the vaccine to maintain potency at ambient temperatures, eliminating the need for cold-chain storage and significantly simplifying distribution and storage operations.
Solution Approach 2:
The inulin acetate microparticle formulation acts as a disposable, stable platform that protects the antigen and maintains vaccine potency without requiring expensive cold-chain infrastructure. The formulation itself provides the necessary stability, making the vaccine suitable for use in resource-limited settings where cold-chain storage is unavailable.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The disclosure provides compositions that include microparticles or nanoparticles of beta inulin or inulin acetate and an active agent, where the active agent is contained within individual microparticles or nanoparticles. The active agent can be, for example, a vaccinating antigen, an antigenic peptide sequence, or an immunoglobulin. The compositions can be incorporated into various formulations for administration to a subject such as a human or animal. The invention further provides methods of using the compositions and formulations, including methods of stimulating an immune response in a subject, or enhancing an immune response in a subject, for the purposes of treating, preventing, or inhibiting an infectious disease, autoimmune disease, immunodeficiency disorder, neoplastic disease, degenerative disease, an aging disease, or a combination thereof.